Zinc and the immune system

Lothar Rink* and Philip Gabriel

Institute of Immunology and Transfusion Medicine, University of Lübeck School of Medicine, Ratzeburger Allee 160, D-23538 Lübeck, Germany

Zn is an essential trace element for all organisms. In human subjects body growth and development is strictly dependent on Zn. The nervous, reproductive and immune systems are particularly influenced by Zn deficiency, as well as by increased levels of Zn. The relationship between Zn and the immune system is complex, since there are four different types of influence associated with Zn. (1) The dietary intake and the resorption of Zn depends on the composition of the diet and also on age and disease status. (2) Zn is a cofactor in more than 300 enzymes influencing various organ functions having a secondary effect on the immune system. (3) Direct effects of Zn on the production, maturation and function of leucocytes. (4) Zn influences the function of immunostimulants used in the experimental systems. Here we summarize all four types of influence on the immune function. Nutritional aspects of Zn, the physiology of Zn, the influence of Zn on enzymes and cellular functions, direct effects of Zn on leucocytes at the cellular and molecular level, Zn-altered function of immunostimulants and the therapeutic use of Zn will be discussed in detail.

Zinc: Immune system

Raulin (1869) showed that Zn is essential for the growth of *Aspergillus niger*. Todd *et al*. (1934) were the first to show that Zn is necessary for the growth and development of rats. Approximately 100 years after the initial observation by Raulin, Prasad *et al*. (1963) described a Zn-deficiency syndrome in children from Persia practising geophagia. The syndrome was characterized by anaemia, hypogonadism, hepatosplenomegalie, skin alterations and growth and mental retardation. The discovery of acrodermatitis enteropathica (a rare autosomal recessive inheritable disease) as a Zn-specific malabsorption syndrome (Neldner & Hambidge, 1975) indicated clearly that these symptoms are related to Zn deficiency. This disease is also accompanied by thymic atrophy resulting in an immune defect and a high frequency of bacterial, viral and fungal infections. Without treatment this disease leads to death within a few years, but pharmacological Zn supplementation can reverse all symptoms (Neldner & Hambidge, 1975).

Nutritional aspects and physiology of zinc

The total body Zn content of human subjects is 2–4 g. However, Zn is referred to as a trace element, as its plasma concentration is only 12–16 μM. In the serum, Zn is predominantly bound to albumin (60 %, low-affinity), α_2-macroglobulin (30 %, high-affinity) and transferrin (10 %; Scott & Bradwell, 1983). The plasma Zn pool is a minor pool, but highly mobile and immunologically important. There is no specialized Zn storage system in the body, and therefore there must be a daily intake of Zn to achieve a steady-state. The distribution of Zn in the body is summarized in Table 1 (Mills, 1989; Favier & Favier, 1990).

The bioavailability of Zn depends on the composition of the diet. Zn is chelated by phytate and phosphate, resulting

Table 1. Zinc content of human organs

Organ	Zn content	
	μg/g organ dry wt	% whole-body Zn
Muscle	51	57·0
Bone	100	29·0
Skin	32	6·0
Liver	58	5·0
Brain	11	1·5
Kidneys	55	0·7
Heart	23	0·4
Hair	150	0·1
Plasma	1	0·1

in a poor resorption from vegetarian food in comparison with meat. Furthermore, the resorption is reduced by increased levels of other bivalent cations, such as Cu, Mg, Ca, Ni, Cd and Fe (Valberg *et al.* 1984; Favier & Favier, 1990). Fe is of special interest, as most pregnant women take Fe supplements, and some studies have shown a correlation between abortion or preterm delivery and Zn deficiency (Mills, 1989; Favier & Favier, 1990; Scholl *et al.* 1993). Thus, interaction between supplements must be taken into account when a single supplement is taken. The Zn content of food also shows a wide variation (Table 2; Favier & Favier, 1990). A balanced diet is therefore important for an adaquate Zn uptake. Variations in the bioavailability of Zn and Zn content make the Zn intake from food difficult to calculate. Health status and age are also important factors in the daily Zn intake. During the growth period, pregnancy and nursing there is an increased requirement for Zn, since Zn is essential for every proliferating cell, and the daily loss by excretion is approximately the same as the daily intake (Table 3; Ziegler *et al.* 1989; German Society of Nutrition, 1995). Zn absorption depends on the concentration in the diet and is about 20–40 % of the daily intake (Mills, 1989). However, there are a number of contradictory recommendations relating to the daily intake of Zn.

The daily intake must be adjusted according to health status, since Zn steady-state is regulated not only by uptake, but also by fluctuations in Zn excretion associated with a number of diseases and with inflammation (Klaiman *et al.* 1981; Yuzbasiyan-Gurkan *et al.* 1989; Weiss *et al.* 1998). Interestingly, healthy elderly subjects have decreased serum Zn levels, which may be due to decreased resorption or increased excretion (Cakman *et al.* 1996). Acute infections lead to a redistribution of Zn to the liver, decreasing the immunologically-important serum pool (Weiss *et al.* 1995).

All these factors may result in an immune deficiency, but there are no specific immunological defects, only inappropriate or inadequate nutrition. However, long-term Zn deficiency due to inappropriate nutrition may result in immunological or autoimmune diseases.

Cell biology of zinc

Exogenous Zn enters the cell within minutes (Wellinghausen *et al.* 1996*b*). However, it is not known how Zn enters the cell. Some specific Zn transporters have been reported in the nervous system, but these transporters inhibit the efflux of the intracellular Zn pool and some have been reported to be involved in intracellular redistribution, but there is no evidence that these transporters are involved in Zn uptake (Palmiter & Findley, 1995; Palmiter *et al.* 1996*a*,*b*; Tsuda *et al.* 1997). The transferrin receptor (CD71) has been reported to promote Zn influx, as for Fe, but this finding has not been confirmed by other workers (Wellinghausen *et al.* 1996*b*). Thus, there are no irrefutable data to indicate that CD71 is a Zn receptor. Different possible mechanisms for Zn uptake such as non-specific Ca channels, facilitated diffusion via amino acids and anionic exchange have been reported (Bentley, 1992; Hogstrand *et al.* 1996). In peripheral blood mononuclear cells (PBMC) exogenously-added Zn increases the free Zn content by about 70 % (Wellinghausen *et al.* 1996*b*), whereas the total Zn uptake is 300–600 %, indicating rapid binding of Zn to intracellular proteins (A Fischer, P Gabriel and L Rink, unpublished results).

Zn is a cofactor for more than 300 enzymes (Coleman, 1992*a*,*b*; Vallee & Falchuk, 1993). In some enzymes Zn is important for structural integrity, whereas in other enzymes it is the central ion for enzymic activity, but sometimes both these functions are involved, as in alcohol dehydrogenase. As a third possibility, Zn modulates the activity of a number of enzymes. Members of all six classes of enzymes use Zn as a cofactor (Table 4). A variety of general cell functions are therefore influenced by the Zn concentration. Factors interacting with DNA and RNA (e.g. transcription and replication factors), particularly, are Zn-dependent, because their structure shows a Zn-finger motif (Table 5). As a result cell proliferation does not occur in the absence of Zn,

Table 2. Zinc content of some foods (mg/100g)

Meat and animal products		Vegetables and plant products	
Beef fillet	3·6	Wheat (white) flour	0·9
Liver	4–6	Wholemeal flour	3·0
Roast beef	2·5	Sugar	0·1
Pork fillet	3·6	Potato	0·2–0·3
Pork cutlet	1·3	Carrot	0·64
Pork shoulder	3·5	Radish	0·16
Calf fillet	4·3	Cauliflower	0·23
Poultry	2–3	Salad	0·22
Fish	1–2	Red cabbage	0·22
Oysters	20–150	Sauerkraut	0·32
Eggs	0·3–0·5	Fruit	0·1–0·3
Milk	0·2–0·4	Vegetable oil	0·1–0·2
Cheese	1–5	Sweetcorn	1·2
Butter	0·15	Coconut	0·5
		Rice	1·3

Table 3. Recommended daily intake of zinc (mg/d; German Society of Nutrition, 1995)

Infants and children:	0–< 12 months	5
	1–< 4 years	7
	4–< 7 years	10
	7–< 10 years	11
	10–< 13 years	12
Adolescents and adults:	Male	15
	Female	12
	Pregnant	15
	Nursing women	22

Table 1. Enzymes with zinc as a co-factor (examples in each enzyme class)

Enzyme	No. of Zn ions and their function	Enzyme class
Alcohol dehydrogenase	One for stability and one for enzyme activity	Oxidoreductase
RNA polymerase	Two for catalytic activity	Transferase
Alkaline phosphatase	Two for catalytic activity and co-activity	Hydrolase
Carbonic anhydrase	One for catalytic activity	Lyase
Aldolase II (fungi)	One for catalytic activity	Isomerase
t-RNA synthetase	One or two for catalytic activity	Ligase

Table 5. Some proteins containing zinc-finger motifs

Molecule containing Zn-fingers	Function	Reference
Oestradiol receptor	Hormone receptor	Humeny *et al.* (1999)
Glucocorticoid receptor	Hormone receptor	Schoenmakers *et al.* (1999)
AIRE-protein	Gene product, probably responsible for autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy	The Finnish-German APECED Consortium (1997)
MTB-Zf	MTB-Zf expression leads to the haem-oxygenase-1 gene product	Muraosa *et al.* (1996)
Myelin transcription factor 1	DNA-binding protein, important for oligodendrocyte development	Armstrong *et al.* (1995)
ZNF7	Lack of this protein expression in Burkitt lymphomas	Feduchi *et al.* (1994)
Z-225 (Egr-1)	Upregulation in RA synoviocytes	Aicher *et al.* (1994), Aicher *et al.* (1999)
WT-1	Expression in myeloid leucaemia and Wilms tumour	Deuel *et al.* (1999)
TFIIIA	Transcription factor	Pavletich & Pabo (1993)
TIEG	Transcription factor	Chalaux *et al.* (1999)
EGR3/Pilot	Transcription factor	Yamagata *et al.* (1994)
RFLAT-1	Transcription factor	Song *et al.* (1999)
mSNA	Transcription factor	Nakayama *et al.* (1998)
YY1	Transcription factor	De-Rinaldis *et al.* (1998)
REST	Transcription factor	Andres *et al.* (1999)
AREB6	Transcription factor	Turner & Crossley (1998)
Gli-1	Transcription factor	Hynes *et al.* (1997)
GATA-6	Transcription factor	Sakai *et al.* (1998)
WZF-1	Transcription factor	Skamoto *et al.* (1996)
RU 49	Transcription factor	Yang *et al.* (1996)
SP 1	Transcription factor	Philipsen & Suske (1999)
BCL 6-protein	Transcription repressor	Chang *et al.* (1996)
ZNF174	Transcription repressor	Williams *et al.* (1995)

RA, rheumatoid arthritis.

and highly-proliferating cell systems, such as the immune system, the skin and the reproductive system, are the most sensitive indicators of Zn deficiency. Furthermore, different factors important for signal transduction need Zn to maintain their normal function; thus, Zn can alter their function, but this change does not necessarily involve a loss of function (Maret *et al*. 1999). Enzymes inhibited by Zn include: caspase-3, fructose-1,6-bisphosphatase, glyceraldehyde-3-phosphase dehydrogenase, aldehyde dehydrogenase, tyrosine phosphatase, enolase. Also, the translocation of protein kinase C (PKC) to the cell membrane is Zn dependent.

More recently, Taylor & Blackshear (1995) reported that Zn influences the stability of mRNA by inhibiting its turnover. The resultant accumulation of mRNA is assumed to regulate gene expression, and might therefore also play a role in Zn-induced effects.

Apoptosis represents a physiological method of cell death. Without apoptosis development is not maintained, the exclusion of autoimmune T-cells and B-cells is lost and the killing activity of cytotoxic T-cells and NK cells decreases. Apoptosis is regulated by Zn and Zn chelation in the culture medium causes apoptosis (Jiang *et al*. 1995; Umezawa *et al*. 1999). On the other hand, the addition of Zn can protect cells against undergoing apoptosis. This protective action has been reported in relation to almost all apoptosis-inducing factors, including tumour necrosis factor-α, cytotoxic T-cells, dexamethasone, withdrawal of interleukin (IL) 2 (in IL-2-dependent T-cell lines), sporidesmin, cold shock, etoposide, hyperthermia, adenosine, and u.v. and γ-irradiation (Zalewski & Forbes, 1993). Interestingly, Zn can inhibit apoptosis even if added a short time after the apoptotic agent. Possible mechanisms for this anti-apoptotic effect are the inhibition of caspase-3, a direct interaction

with bcl-2, or an induction of DNA synthesis by Zn (Fukamachi *et al*. 1998; Ishido *et al*. 1999; Maret *et al*. 1999). Other anti-apoptotic mechanisms suggested for Zn, are Ca antagonism, inhibition of the Ca^{2+}/Mg^{2+}-endonuclease and an interaction between Zn-finger proteins and the microtubuli system (Zalewski & Forbes, 1993). It is possible that Zn has various independent anti-apoptotic effects and that cell activation alone can prevent apoptosis. During the early stages of apoptosis there is a major redistribution of intracellular Zn. The increase in free Zn in the cytosol is a result of Zn release from intracellular pools and metalloenzymes (Maret, 1998).

All these effects of Zn are very important for the highly-proliferative and physiologically-active leucocytes, but they are not restricted to the cells of the immune system. However, a slightly decreased Zn status might be associated initially with immunological effects, in the form of an increased number of infections.

Specific interactions of zinc within the immune system

It has been established that Zn is an essential trace element for the immune system. However, the cellular and molecular mechanisms for the role of Zn within the immune system have been elucidated only during the last 10 years.

The innate as well as the specific parts of the immune system are influenced by Zn. The effects of Zn are multi-faceted. Zn can induce adhesion of myelomonocytic cells to the endothelium, while Zn chelation diminishes cell recruitment (Chavakis *et al*. 1999). Thus, Zn is essential even in the earliest stages of an immune response. *In vivo*, Zn deficiency not only influences the recruitment of neutrophils but also decreases the chemotaxis of neutrophils. Under these conditions there is also impaired natural

killer cell activity, phagocytosis of macrophages and neutrophils, and generation of the oxidative burst (Allen *et al.* 1983; Keen & Gershwin, 1990). At the molecular level, Zn is required for the interaction between the p58 killer cell inhibitory receptor on NK cells and major histocompatibility complex (MHC) class I molecules, mainly human leucocyte antigen C, on target cells (Rajagopalan *et al.* 1995), resulting in the inhibition of the killing activity. Interestingly, only the inhibitory signal is Zn-dependent, whereas the human leucocyte antigen C interaction and positive signals do not require Zn (Rajagopalan *et al.* 1995). Thus, Zn is needed to maintain the normal function of natural killer cells, and Zn deficiency may result in non-specific killing activity and functional loss. It is not only the proliferation of the immune system which depends on Zn; the proliferation of the pathogens is also Zn-dependent. Thus, decreasing Zn in the plasma is an acute-phase response to infection. Furthermore, the S-100 Ca^{2+}-binding protein calprotectin which is released by degradation of neutrophils inhibits reproduction of bacteria and *Candida albicans* by Zn chelation (Sohnle *et al.* 1991; Murthy *et al.* 1993; Clohessy & Golden, 1995).

Despite the fact that innate immunity is the first stage in the response of the immune system, initial observations relating to the influence of Zn were associated with the development of T-cells due to thymic atrophy (Fraker *et al.* 1995; Osati-Ashtiani *et al.* 1998). Zn is an essential cofactor for the thymic hormone thymulin (a nonapeptide) (Bach, 1981, 1983). Thymulin is secreted by thymic epithelial cells and induces markers of differentiation in immature T-cells (Saha *et al.* 1995). However, thymulin also modulates cytokine release by PBMC and induces proliferation of CD8 T-cells in combination with IL-2 (Coto *et al.* 1992; Safie-Garabedian *et al.* 1993). Zn supplementation can reverse the changes induced by Zn deficiency in the thymus and on peripheral cells (Mocchegiani *et al.* 1995a). The addition of Zn alone can induce the expression of the high-affinity receptor for IL-2 (Tanaka *et al.* 1989); a factor which can result in decreased proliferation of T-cells in Zn deficiency (Dowd *et al.* 1986; Crea *et al.* 1990).

Zn ions have been reported to induce blast transformation in human lymphocytes (Kirchner & Rühl, 1970; Rühl *et al.* 1971; Berger & Skinner, 1974; Sood *et al.* 1999). Zn addition induced the release of IL-1, IL-6, tumour necrosis factor α, soluble IL-2 receptor and interferon (IFN)-γ in human PBMC (Salas & Kirchner, 1987; Scuderi, 1990; Driessen *et al.* 1994). IL-1, IL-6, and tumour necrosis factor α are induced in monocytes in the absence of lymphocytes, whereas the induction of IFN-γ is dependent on the presence of monocytes (Rühl & Kirchner, 1978; Salas & Kirchner, 1987; Driessen *et al.* 1994; Wellinghausen *et al.* 1997b; Fig. 1). Tumour necrosis factor α release after Zn stimulation of PBMC is a result of *de novo* mRNA transcription (Wellinghausen *et al.* 1996a). However, how Zn activates an intracellular signal and which signal transduction pathways are involved are still unknown. Further investigations showed that only isolated monocytes respond to Zn stimulation, whereas isolated T-cells (Hadden, 1995; Wellinghausen *et al.* 1997b), B-cells (Crea *et al.* 1990), natural killer cells (Crea *et al.* 1990) or neutrophils (A Fischer, P Gabriel and L Rink, unpublished results; Fig. 1)

do not produce cytokines after induction with Zn. The stimulation of monocytes and T-cells by Zn is dependent on the level of free Zn ions relative to the protein composition of the culture medium. Insulin and transferrin specifically enhance Zn-induced monocyte activation by a non-receptor-dependent mechanism (Phillips & Azari, 1974; Crea *et al.* 1990; Driessen *et al.* 1995c; Wellinghausen *et al.* 1996b), but high levels of serum proteins in the culture medium prevent monocyte stimulation. Zn concentrations > 100 μM in a serum-free culture medium stimulate monocytes, but actually inhibit T-cell functions, since T-cells have a lower intracellular Zn concentration and are more susceptible to increasing Zn levels than monocytes (Bulgarini *et al.* 1989; Goode *et al.* 1989; Wellinghausen *et al.* 1997b; Fig. 1). The increase in intracellular free Zn in monocytes and T-cells is the same (Wellinghausen *et al.* 1996b, 1997b). The molecular background for this effect is the inhibition of the IL-1 type I receptor-associated kinase by Zn, since T-cell stimulation by Zn is an indirect effect of IL-1 secreted by monocytes (Driessen *et al.* 1994; Wellinghausen *et al.* 1997b). Furthermore, Zn can alter the structure of ceramides (U Seydel, unpublished results) which are involved in the signal transduction of tumour necrosis factor and IL-1 (Wright & Kolesnick, 1995). This effect is comparable with the conformational alteration of lipopolysaccharide (LPS), described later (Table 5; Wellinghausen *et al.* 1996c). In contrast to the amplifying effect on LPS, the function of ceramides as second messengers may be reduced and could be responsible also for the inhibition of tumour necrosis factor-induced apoptosis (Flieger *et al.* 1990).

As *in vitro*, an excess of Zn *in vivo* inhibits T-cell function (Duchateau *et al.* 1981; Chandra, 1984). *In vitro* levels > 50 μM inhibit alloreactivity in the mixed lymphocyte reaction (aCampo *et al.* 2000). On the other hand, low serum Zn levels also alter normal T-cell functions. Some autoimmune diseases with a T-cell pathology, e.g. rheumatoid arthritis, are associated with moderate Zn deficiency (Simkin, 1976), and in some cases Zn supplementation was advantageous. Decreased plasma Zn levels in preganancy are associated with an increased


Fig. 1. Leucocyte activity and its dependence on plasma zinc concentrations. (▨), lymphocytes; (■), monocytes; (▨), granulocytes. Note that zinc activates monocytes to a greater extent than either granulocytes or lymphocytes.

risk of preterm delivery and abortion (Favier, 1992; Jameson, 1993; Bedwal & Bahuguna, 1994). This factor might be an effect of normally-suppressed alloreactive T-cells or non-specific natural killer cell activity. The physiological Zn concentrations, based on *in vitro* experiments, seem to be just below the optimal concentration for T-cell function (Fig. 1).

In contrast to the mechanisms involved in the inhibition of leucocytes, the direct activation of monocytes by Zn is still not understood. Tyrosine kinases as well as cAMP- and cGMP-dependent protein kinases are clearly involved (Wellinghausen *et al*. 1996*b*). Intracellular cAMP and calmodulin are therefore influenced in a different manner (Brewer *et al*. 1979; Heng *et al*. 1993). Inhibition of intra-erythrocytic calmodulin-mediated effects is possibly responsible for the benefits of Zn supplementation in sickle cell disease (Brewer & Bereza, 1982). In phospholipase C, Zn is integrated, in the active centre, but no stimulatory effects of Zn have been reported (Coleman, 1992*a*). Zn is necessary for the translocation of the PKC to the cell membrane, but an involvement of PKC in Zn-induced signal transduction in PBMC has not been confirmed (Csermely *et al*. 1988; Wellinghausen *et al*. 1996*b*).

Zn might simply bind to specific membrane receptors, triggering a signal transduction cascade. On the other hand, however, Zn could also exert its effects directly inside the cell. Perhaps more important than a specific interaction between Zn and certain molecules is a general influence of Zn on the fluidity of lipids, and thus also of biological membranes (Chvapil, 1976; Kruse-Jarres, 1989; Bettger & O'Dell, 1993). Membrane stabilization could have considerable consequences for the cell; for example, an activation or inhibition of ion channels and altered assembling of cell surface receptors, initiating or inhibiting signal transduction into the cell (Heldin, 1995).

In addition to its effects on upstream signalling molecules, Zn influences gene expression by structural stabilization and functional regulation of various immunologically-relevant transcription factors (Chesters, 1992; Coleman, 1992*a*; O'Halloran, 1993; Vallee & Falchuk, 1993) as summarized earlier. However, the relationship between activation of specific transcription factors and Zn-induced effects in PBMC still remains to be clarified.

Interaction of zinc with immunostimulants

The capacity of the immune system is measured using different outcome systems (e.g. proliferation, cytokine production) after stimulation of leucocytes *in vivo* or *in vitro*. Frequently used stimulants include lectins (e.g. phytohaemagglutinin; PHA), phorbol esters (e.g. phorbol 12-myristate 13-acetate), LPS, super-antigens (e.g. staphylococcal enterotoxins) or specific antigens inducing a recall response in most individuals (e.g. tetanus toxin or diphtheria toxin). Thus, to measure Zn-specific alterations of immune function it must be established that the immunostimulant itself is not affected by Zn. Indeed, the activity of many stimulants is influenced by Zn. Interestingly, one of the early reports regarding the immunobiology of Zn described the co-mitogenic effect of PHA (Duchateau *et al*. 1981; Fraker *et al*. 1986; Warner & Lawrence, 1986).

However, PHA is frequently used *in vitro*, but does not appear in human blood *in vivo*. Thus, it is of greater relevance that Zn influences the immunostimulative effects of LPS from Gram-negative bacteria and some bacterial super-antigens (mainly produced by Gram-positive bacteria), as well as tetanus toxin and diphtheria toxin. Substimulatory concentrations of Zn enhanced the biological activity of LPS with respect to cytokine induction in leucocytes (Driessen *et al*. 1995*a*,*b*). This synergism depends on a Zn-induced structural alteration of LPS in its biologically-more-active less-fluid form (Wellinghausen *et al*. 1996*c*). LPS is an important pathogenic factor in sepsis, and Zn supplementation in patients with systemic Gram-negative infections or in intensive-care-unit patients may have devastating consequences if the activity of LPS is also enhanced *in vivo*. Recently, it was shown that parenteral Zn supplementation (30 mg/d) in septic patients exaggerated the acute-phase response, as indicated by a higher febrile response (Braunschweig *et al*. 1997). However, Klosterhalfen *et al*. (1996) reported that in a porcine sepsis model the induction of stress proteins by prophylactic administration of Zn can reduce the inflammatory response after LPS treatment. We recently found a time-dependent response in a mouse model (P Gabriel, J Schürman, G Tiegs and L Rink, unpublished results). If Zn is injected some minutes before LPS is administered it has a protective effect, whereas application simultaneously with or after LPS treatment resulted in a synergistic effect, as described earlier (Wellinghausen *et al*. 1996*c*). This finding may be explained by the influence of Zn on the IL-1 type 1 receptor-associated kinase as described earlier (p. 544), since the LPS signal transduction pathway via the toll-like receptors (members of the IL-1 receptor family) are also dependent on this kinase. Thus, Zn might be useful in the prophylactic treatment of patients at high-risk for sepsis, but unsuitable for already-septic patients.

The activity of some bacterial super-antigens is also influenced by Zn (Driessen *et al*. 1995*a*,*b*). There are different groups of super-antigens using binding sites on the MHC-II α-chain, β-chain, or both sites. All super-antigens binding to the MHC-II β-chain (e.g. the *Staphylococcus aureus* enterotoxins A, D and E and the *Mycoplasma arthritidis* super-antigen) do so by forming a Zn cluster involving histidine-81 of the MHC-II β-chain and three amino acids from the super-antigen (Fraser *et al*. 1992; Kim *et al*. 1994; Sundström *et al*. 1996; Bernatchez *et al*. 1997). Thus, binding to the MHC-II β-chain is Zn-dependent. The interaction between these super-antigens and the MHC-II β-chain can be diminished by the chelation of Zn (Bernatchez *et al*. 1997). On the other hand, cytokine induction by those super-antigens can also be inhibited by the addition of high Zn concentrations (Driessen *et al*. 1995*b*), whereas super-antigens binding to the Zn-independent MHC-II α-binding site (e.g. toxic shock syndrome toxin-1) are not influenced by Zn in any way. Without Zn the super-antigens cannot build up a Zn cluster with histidine-81 of the MHC-II β-chain, and it is likely that high Zn concentrations saturate both sites, thus preventing complex formation. However, Zn also mediates a super-antigen homodimerization, as recently described for *S. aureus* enterotoxins (Sundström *et al*. 1996). This homodimerization facilitates a T-cell-

independent interaction between the super-antigen and MHC-II molecules, resulting in direct activation of monocytes. The inhibitory effect of Zn on super-antigens could be an interesting therapeutic perspective for the treatment of food poisoning, Gram-positive sepsis or staphylococcal infections in which super-antigens play a causative role. Furthermore, the production of some super-antigens (e.g. toxic shock syndrome toxin-1) seems to be regulated by Zn repressor elements, since Zn chelation increases the super-antigen production (Tierno & Hanna, 1985; Balaban & Novick, 1995; Balaban *et al.* 1998). Interestingly, diphtheria-toxin production is also regulated by a Zn repressor (Groman & Judge, 1979; Pohl *et al.* 1997).

Phorbol 12-myristate 13-acetate, tetanus toxin and diphtheria toxin may also be influenced by Zn, but there are no conclusive data available. Phorbol 12-myristate 13-acetate directly activates PKC, and PKC is influenced by Zn as described earlier (p. 545). Tetanus toxin has a Zn-binding sequence in a region frequently used as a B- and T-cell epitope (Villiers *et al.* 1993). Zn saturation of this binding site leads to decreased recognition by antibodies and T-cells. Thus, Zn saturation of tetanus toxin may influence the outcome after tetanus toxin stimulation.

However, it is not only immunostimulants that are affected by Zn, since cytokine functions and detection are modulated by Zn-activated α_2-macroglobulin, which may also alter the outcome (James, 1990). In conclusion, it is difficult to find an immunostimulant and test system completely independent of Zn in its function *in vivo* or *in vitro*.

Zinc therapy and *in vitro* zinc supplementation

Zn has diverse effects on immune functions. During Zn deficiency different immune functions are decreased (Table 6; Wellinghausen *et al.* 1997*a*). All these impaired functions are completely restored by Zn supplementation. Since the defect in some immunological functions is related to a lack of the relevant leucocyte subset, only some of the functions were restored *in vitro* (Cakman *et al.* 1996, 1997).

Zn administration is the standard therapy for acrodermatitis enteropathica, as well as in non-specific malabsorption syndromes (Neldner & Hambidge, 1975; Cunningham-Rundles *et al.* 1980). The Zn supplement reversed immunological defects as well as other Zn-deficiency-associated syndromes. Furthermore, Zn supplementation is frequently used to compete with Cu for absorption in Wilson's diseases and to increase metallothionein.

Table 6. Immune functions which are decreased in zinc deficiency

Periperhal T-cell count
T-cell proliferation in response to PHA
Thymocyte count in thymus
Delayed-type hypersensitivity reaction
T-helper cell function
Cytotoxic T-cell activity
NK cell activity
Macrophage functions (phagocytosis, intracellular killing activity)
Neutrophil functions (chemotaxtis, oxidative burst)
Serum thymulin level

PHA, phytohaemagglutinin; NK, natural killer.

Various diseases are accompanied by altered Zn plasma levels. For some diseases the results of preliminary trials of Zn therapy have been published. Tables 7 and 8 summarize the diseases, the effects of Zn and the possible molecular mechanism associated with the beneficial effects of Zn therapy.

An interesting application of Zn is its use as an adjuvant in vaccination. Two groups of patients with reduced plasma Zn levels (the elderly, and haemodialysis patients) are known to have an impaired immune system and a poor response to vaccination (Sandstead *et al.* 1982; Lighart *et al.* 1984; Fraker *et al.* 1986; Bonomini *et al.* 1993; Cakman *et al.* 1996). The results of a number of vaccination trials which were accompanied by Zn supplementation have been published during the last two decades (Rawer *et al.* 1987; Grekas *et al.* 1992; Brodersen *et al.* 1995; Provinciali *et al.* 1998; Turk *et al.* 1998). The findings were extremely contradictory. This situation may be due to the lack of a standard level for Zn supplementation. In some studies extremely high (400 mg/d) levels of Zn were given, which have been shown in other trials to impair immune functions (reduced delayed-type hypersensitivity reaction occurs at a dose of 100 mg/d; Porter *et al.* 1977; Chandra, 1984; Patterson *et al.* 1985; Provinciali *et al.* 1998; Reinhold *et al.* 1999; Rink & Kirchner, 1999). We recently found that the response to diphtheria vaccination in haemodialysis patients is correlated with the actual plasma Zn level (Kreft *et al.* 2000). Possible mechanisms for this relationship are an increase in IFN-α production, as shown *in vitro*, or impaired T-cell functions (Sandstead *et al.* 1982; Cakman *et al.* 1996). However, high-dose Zn supplementation (seven to eight times the physiological level) *in vitro* inhibited T-cell functions and reduced IFN-α production. Thus, in order to reverse Zn deficiency, the pharmacological Zn dose should be adjusted in line with the actual requirements, and plasma Zn level should not exceed 3 0μM.

The inhibitory effects of Zn may provide a new therapeutic tool for use in immunosuppressive therapy where a selective suppression of lymphocyte functions is desirable. Possible diseases are T-cell-mediated autoimmune diseases such as rheumatoid arthritis or graft *v*. host reactions following organ transplantation. We observed that Zn specifically inhibits the mixed lymphocyte culture (as an *in vitro* transplantation model) at concentrations of three to four times the physiological level.

Conclusion

It has been known for decades that Zn is essential for an intact immune system. However, experimental data and nutritional explanations for the precise function and daily intake requirements are few or contradictory. The problem is the differentiation of the effects of Zn on general cell growth and function, the specific effects on cells of the immune system or alterations of the outcome system via an effect on the immunostimulants. Furthermore, normal immune function is delicately regulated by the Zn level, and Zn deficiency, as well as Zn levels >50μM, alter normal immune functions. Fig. 1 shows that the function of leucocytes is dependent on the Zn concentration. Thus, therapeutic Zn administration must be adjusted according

Table 7. Zinc therapy studies

Disease or disorder	Symptoms	Effect of Zn supplementation	Possible mechanism	Reference
Cutaneous leishmaniasis	Ulcerative lesions susceptible to secondary infections	Decrease of disease activity	Leishmania is sensitive to zinc sulfate	Najim et al. (1998)
Growth retardation	Deficiency in the secretory activity of the testis, hypogonadism (male)	Recovery of testical functions, normalization of overall growth	Reactivation of enzymes and transcription factors	Prasad (1995, 1996)
Cystic fibrosis	Impaired Zn absorption	Improved Zn absorption by enzyme replacement	Re-activation of enzymes and transcription factors	Easley et al. (1998)
Parkinson's disease	Tremor	Reduction of Parkinson symptoms	Inhibition of β-carboline-2-N-methyltransferase	Gearhart et al. (1997)
Wilson's disease (WD)	Kayser-Fleischer-rings (cornea), muscle rigidity and dementia	Reduces Cu absorption and Kayser-Fleischer rings in size. Increases metallothionein in presymptomatic WD patient	Inhibits Cu resorption Induced metallothionein synthesis which also prevents Cu accumulation	Brewer & Yuzbasiyan-Gurkan (1992), Brewer et al. (1994), Esmaeli et al. (1996), Shimizu et al. (1999), Sturniolo et al. (1999)
Sickle cell disease	Hyperzincuria causes an impaired cell-mediated immunity	Increase in lymphocyte function and IL-2 production. Decreased hospitalizations and vaso-occlusive pain	Reconstitution of thymocyte functions	Prasad et al. (1999)
Common cold	Rhinitis, tearing, low-grade fever and malaise	Zinc gluconate reduces the duration of symptoms	Cell membrane stabilization to reduce viral penetration. Altered viral capsid formation. Increased IFN-α production	Mossad et al. (1996), Cakman et al. (1997)
Hypozincaemia	Increased incidence of concomitant systematic bacterial infections	Zn supplementation can reduce bacterial infections	Reconstitution of thymocyte functions, increased NK and phagocytotic activity	Worwag et al. (1999)
Acrodermatitis enteropathica	Vesicles and bullae of the skin and mucous membranes, alopecia, diarrhoea and failure to thrive. Autosomal recessive disorder of Zn resorption	Zn therapy reverses all symptoms	Reactivation of enzymes and transcription factors, reconstitution of thymocyte functions, increased NK and phagocytotic activity	Prasad (1995)
AIDS	Increased apoptosis of immune cells. Hypozincaemia associated with increased opportunistic infections	Decreased apoptosis and Zn is an adjunct to AZT therapy in AIDS pathology	Zn inhibits T-cell apoptosis and increases thymocyte proliferation	Mocchegiani et al. (1995b), Neves et al. (1998), Wellinghausen et al. (2000)
Rheumatoid arthritis (RA)	Lower level of Zn may be due to an accumulation of Zn-containing proteins in the liver and in the inflamed joints in RA	Decreased symptoms	Impairment of PMN phagocytosis, T-cell suppression and blocking IL-1 signal transduction	Zoli et al. (1998), Wellinghausen et al. (1997b)
Herpes simplex virus	Small, transient, irritating and sometimes painful fluid-filled blisters on the skin and mucous membranes	Shortening infection	Inhibition of virion functions by binding to sulfhydryl groups of glycoprotein B and increased IFN-α production	Varadinova et al. (1993), Cakman et al. (1996)
Down syndrome	Immature myeloid cells in the peripheral blood	Haematological symptoms reversed	Direct effects on leucocytes and on thymus hormones	Trubiani et al. (1996), Antonucci et al. (1997)
Crohn's disease	Decreased Zn levels lead to acrodermatitis enteropathica and decreased visual acuity	Alleviation of skin lesions and improvement of visual acuity. Low plasma concentrations of thymulin restored	T-cell suppression and thymus reconstitution	Brignola et al. (1993), Krasovec & Frenk (1996), Myung et al. (1998)

AIDS, acquired immune deficiency syndrome; AZT, zidovudine; IL, interleukin; IFN, interferon; NK, natural killer; PMN, polymorphonuclear leucocyte.

to the plasma Zn level. On the other hand, Zn can be used as an immunosuppressant with low toxicity. Last, but not least, both *in vivo* and *in vitro* the adequacy of the Zn concentration must be taken into account whenever abnormal cellular functions are observed. This approach is not restricted to the immune system, but the immune system is the first system to be affected by changing Zn levels, due to its high cell turnover.

Table 8. Diseases associated with altered zinc levels

Disease	Plasma Zn level	Type of disorder	Reference
Alzheimer's disease	elevated	Zn-mediated NF-kB activation resulting in the activation of the amyloid precursor protein (APP) promoter region. APP forms amyloid-β and Zn inhibits the modulation of APP into non-amyloidogenic peptides. Amyloid-β-protein forms Ca-permeable and Zn-sensitive channels resulting in cellular toxicity	Kawahara *et al.* (1997), Lin *et al.* (1999)
Hyperzincaemia	elevated	Plasma levels $> 200\,\mu M$ cause symptoms consistent with Zn deficiency, probably an inborn defect of Zn metabolism	Sampson *et al.* (1997)
Depression	decreased	Zn deficiency impairs neuro- and immunoactivity of the mammalian organisms. Hypozincaemia in severe depression may be related to activation of cell-mediated immunity in that illness. T-cell suppression and modulation of neurotransmitter systems	Nowak (1998), Nowak & Schlegel-Zawadzka (1999)
Preterm delivery	decreased	Decreased plasma Zn levels are associated with preterm delivery and abortion	Scholl *et al.* (1993)

References

aCampo C, Wellinghausen N, Faber C, Fischer A & Rink L (2000) Zinc inhibits the mixed lymphocyte culture. *Biological Trace Element Research* (In the Press).

Aicher WK, Heer AH, Trabandt A, Bridges SL Jr, Schroeder HW Jr, Stransky G, Gay RE, Eibel H, Peter HH, Siebenlist U, Koopman WJ & Gay S (1994) Overexpression of zinc-finger transcription factor z-225/Egr-1 in synoviocytes from rheumatoid arthritis patients. *Journal of Immunology* **152**, 5940–5948.

Aicher WK, Sakamoto KM, Hack A & Eibel H (1999) Analysis of functional elements in the human Egr-1 gene promoter. *Rheumatology International* **8**, 207–214.

Allen JI, Perri RT, McClain CJ & Kay NE (1983) Alterations in human natural killer cell activity and monocyte cytotoxicity induced by zinc deficiency. *Journal of Laboratory and Clinical Medicine* **102**, 577–589.

Andres ME, Burger C, Peral-Rubio MJ, Battaglioli E, Anderson ME, Grimes J, Dallman J, Ballas N & Mandel G (1999) CoREST: a functional corepressor required for regulation of neural-specific gene expression. *Proceedings of the National Academy of Sciences USA* **96**, 9873–9878.

Antonucci A, Di-Baldassarre A, Di-Giacomo F, Stuppia L & Palka G (1997) Detection of apoptosis in peripheral blood cells of 31 subjects affected by Down syndrome before and after zinc therapy. *Ultrastructural Pathology* **21**, 449–452.

Armstrong RC, Kim JG & Hudson LD (1995) Expression of myelin transcription factor I (MyTI), a 'zinc-finger' DNA-binding protein, in developing oligodendrocytes. *Glia* **14**, 303–321.

Bach JF (1981) The multi-faceted zinc dependency of the immune system. *Immunology Today* **4**, 225–227.

Bach JF (1983) Thymulin (FTS-Zn). *Clinics in Immunology and Allergy* **3**, 133–150.

Balaban N, Goldkorn T, Nhan RT, Dang LB, Scott S, Ridgley RM, Rasooly A, Wright SC, Larrick JW, Rasooly R & Carlson JR (1998) Autoinducer of virulence as a target for vaccine and therapy against *Staphylococcus aureus*. *Science* **280**, 438–440.

Balaban N & Novick RP (1995) Autocrine regulation of toxin synthesis by *Staphylococcus aureus*. *Proceedings of the National Academy of Sciences USA* **92**, 1619–1623.

Bedwal RS & Bahuguna A (1994) Zinc, copper and selenium in reproduction. *Experientia* **50**, 626–640.

Bentley PJ (1992) Influx of zinc by channel catfish (*Ictalurus punctatus*): uptake from external environmental solutions. *Comparative Biochemistry and Physiology* **101**C, 215–217.

Berger NA & Skinner M (1974) Characterization of lymphocyte transformation induced by zinc ions. *Journal of Cellular Biology* **61**, 45–55.

Bernatchez C, Al-Daccak R, Mayer PE, Mehindate K, Rink L, Mecheri S & Mourad W (1997) Functional analysis of *Mycoplasma arthritidis*-derived mitogen interaction with class II molecules. *Infection and Immunity* **65**, 2000–2005.

Bettger WJ & O'Dell BL (1993) Physiological roles of zinc in the plasma membrane of mammalian cells. *Journal of Nutritional Biochemistry* **4**, 194–207.

Bonomini M, Di Paolo B, De Risio F, Niri L, Klinkmann H, Ivanowich P & Albertazzi A (1993) Effects of zinc supplementation in chronic haemodialysis patients. *Nephrology Dialysis and Transplantation* **8**, 1166–1168.

Braunschweig CL, Sowers M, Kovacevich DS, Hill GM & August DA (1997) Parenteral zinc supplementation in adult humans during the acute phase response increases the febrile response. *Journal of Nutrition* **127**, 70–74.

Brewer GJ, Aster JC, Knutsen CA & Kruckeberg WC (1979) Zinc inhibition of calmodulin: a proposed molecular mechanism of zinc action on cellular functions. *American Journal of Hematology* **7**, 53–60.

Brewer GJ & Bereza UL (1982) Therapy of sickle cell anemia with membrane expander/calmodulin inhibitor classes of drugs. In *Clinical, Biochemical, and Nutritional Aspects of Trace Elements*, pp. 211–220 [AS Prasad, editor]. New York: Liss.

Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Johnson V & Wang Y (1994) Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis. *Journal of Laboratory and Clinical Medicine* **123**, 849–858.

Brewer GJ & Yuzbasiyan-Gurkan V (1992) Wilson disease. *Medicine* **71**, 139–164.

Brignola C, Belloli C, DeSimone G, Evangelisti A, Parente R, Mancini R, Innan P, Mocchegiani E, Fabris N & Morini MC (1993) Zinc supplementation restores plasma concentrations of zinc and thymulin in patients with Crohn's disease. *Alimentary and Pharmacology and Therapeutics* **7**, 275–280.

Brodersen HP, Holtkamp W, Larbig D, Beckers B, Thiery J, Lautenschlager J, Probst HJ, Ropertz S & Yavari A (1995) Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients a multicentre study. *Nephrology Dialysis Transplantation* **10**, 1780.

Bulgarini D, Habetswallner D, Boccoli G, Montesoro E, Camagna A, Mastroberardino G, Rosania C, Testa U & Peschle C (1989) Zinc modulates the mitogenic activation of human peripheral blood lymphocytes. *Annali dell Istituto Superiore di Sanita* **25**, 463–470.

Cakman I, Kirchner H & Rink L (1997) Zinc supplementation reconstitutes the production of interferon-α by leukocytes from elderly persons. *Journal of Interferon and Cytokine Research* **17**, 469–472.

Cakman I, Rohwer J, Schütz RM, Kirchner H & Rink L (1996) Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. *Mechanisms of Ageing and Development* **87**, 197–209.

Chalaux E, Lopez-Rovira T, Rosa JL, Pons G, Boxer LM, Batrons R & Ventura F (1999) A zinc-finger transcription factor induced by TGF-beta promotes apoptotic cell death in epithelial Mv1Lu cells. *FEBS Letters* **457**, 478–482.

Chandra RK (1984) Excessive intake of zinc impairs immune responses. *Journal of the American Medical Association* **252**, 1443–1446.

Chang CC, Ye BH, Chaganti RS & Dalla-Favera R (1996) BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. *Proceedings of the National Academy of Sciences USA* **93**, 6947–6952.

Chavakis T, May AE, Preissner KT & Kanse SM (1999) Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and β_2-integrins. *Blood* **93**, 2976–2983.

Chesters JK (1992) Trace elements–gene interactions. *Nutrition Reviews* **50**, 217–223.

Chvapil M (1976) Effect of zinc on cells and biomembranes. *Medical Clinics of North America* **60**, 799–812.

Clohessy PA & Golden BE (1995) Calprotectin-mediated zinc chelation as a biostatic mechanism in host defense. *Scandinavian Journal of Immunology* **42**, 551–556.

Coleman JE (1992a) Zinc proteins: Enzymes, storage proteins, transcription factors and replication proteins. *Annual Review of Biochemistry* **16**, 897–946.

Coleman JE (1992b) Structure and mechanism of alkaline phosphatase. *Annual Review of Biophysics and Biomolecular Structure* **21**, 441–483.

Coto JA, Hadden EM, Sauro M, Zorn N & Hadden JW (1992) Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C. *Proceedings of the National Academy of Sciences USA* **89**, 7752–7756.

Crea A, Guérin V, Ortega F & Hartemann P (1990) Zinc et système immunitaire (Zinc and immune system). *Annales de Medecine Interne* **141**, 447–451.

Csermely P, Szamel M, Resch K & Somogyi J (1988) Zinc can increase the activity of protein kinase C and contributes to its binding to plasma membrane in T lymphocytes. *Journal of Biological Chemistry* **263**, 6487–6490.

Cunningham-Rundles S, Bockman RS, Lin A, Giardina PV, Hilgartner MW, Caldwell-Brown D & Carter DM (1980) Physiological and pharmacological effects of zinc on immune response. *Annals of the New York Academy of Sciences* **587**, 113–122.

De-Rinaldis E, Pisaneschi G, Camacho-Vanegas O & Beccari E (1998) The binding sites for *Xenopus laevis* FIII/YY1 in the first exon of L1 and L14 ribosomal protein genes are dispensable for promoter expression. *European Journal of Biochemistry* **255**, 563–569.

Deuel TF, Guan LS & Wang ZY (1999) Wilms tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain. *Biochemical and Biophysical Research Communications* **254**, 192–196.

Dowd PS, Kelleher J & Guillou PJ (1986) T-lymphocyte subsets and interleukin-2 production in zinc-deficient rats. *British Journal of Nutrition* **55**, 59–69.

Driessen C, Hirv K, Kirchner H & Rink L (1995a) Divergent effects of zinc on different bacterial pathogenic agents. *Journal of Infectious Diseases* **171**, 486–489.

Driessen C, Hirv K, Kirchner H & Rink L (1995b) Zinc regulates cytokine induction by superantigens and lipopolysaccharide. *Immunology* **84**, 272–277.

Driessen C, Hirv K, Rink L & Kirchner H (1994) Induction of cytokines by zinc ions in human peripheral blood mononuclear cells and separated monocytes. *Lymphokine and Cytokine Research* **13**, 15–20.

Driessen C, Hirv K, Wellinghausen N, Kirchner H & Rink L (1995c) Influence of serum on zinc, toxic shock syndrome toxin-1, and lipopolysaccharide-induced production of IFN-γ and IL-1β by human mononuclear cells. *Journal of Leukocyte Biology* **57**, 904–908.

Duchateau J, Delespesse G & Vereecke P (1981) Influence of oral zinc supplementation on the lymphocyte response to mitogens of normal subjects. *American Journal of Clinical Nutrition* **34**, 88–93.

Easley D, Krebs N, Jefferson M, Miller L, Erskine J, Accurso F & Hambidge KM (1998) Effect of pancreatic enzymes on zinc absorption in cystic fibrosis. *Journal of Pediatric Gastroenterology and Nutrition* **26**, 136–139.

Esmaeli B, Burnstine MA, Martonyi CL, Sugar A, Johnson V & Brewer GJ (1996) Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestation of WD. *Cornea* **15**, 582–588.

Favier A & Favier M (1990) Consequences des deficits en zinc durant la grossesse pour la mère et le nouveau-né (Consequences of zinc deficits during pregnancy for the mother and newborn). *Revue Française de Gynecologie et d'Obstetrique* **85**, 13–27.

Favier AE (1992) The role of zinc in reproduction. Hormonal mechanisms. *Biological Trace Element Research* **32**, 363–382.

Feduchi E, Gallego MI & Lazo PA (1994) The human zinc-finger protein-7 gene is located 90 kb 3′ of MYC and is not expressed in Burkitt lymphoma cell lines. *International Journal of Cancer* **58**, 855–859.

Flieger D, Riethmüller G & Ziegler-Heitbrock HWL (1990) Zn^{2+} inhibits both tumor necrosis factor-mediated DNA fragmentation and cytolysis. *International Journal of Cancer* **44**, 315–319.

Fraker PJ, Gershwin ME, Good RA & Prasad A (1986) Interrelationships between zinc and immune functions. *Federation Proceedings* **45**, 1474–1479.

Fraker PJ, Osati-Ashtiani F, Wagner MA & King LE (1995) Possible roles for glucocorticoids and apoptosis in the suppression of lymphopoiesis during zinc deficiency: a review. *Journal of the American College of Nutrition* **14**, 11–17.

Fraser JD, Urban RG, Strominger JL & Robinson H (1992) Zinc regulates the function of two superantigens. *Proceedings of the National Academy of Sciences USA* **89**, 5507–5511.

Fukamachi Y, Karasaki Y, Sugiura T, Itoh H, Yamamura K & Higashi K (1998) Zinc suppresses apoptosis of U937 cells induced by hydrogen peroxide through an increase of the Bcl-2/Bax ratio. *Biochemical and Biophysical Research Communications* **246**, 364–369.

Gearhart DA, Neafsey EJ & Collins MA (1997) Characterization of brain beta-carboline-2-N-methyltransferase, an enzyme that may play a role in idiopathic Parkinson's disease. *Neurochemical Research* **22**, 113–121.

German Society of Nutrition (1995) Ausschuß Nahrungsbedarf der DGE Zufuhrempfehlungen und Nährstoffbedarf. Teil II: Vergleich der Vorschläge von SCF/EC mit den Empfehlungen der DGE (Dietary requirements committee of DGE recommended intakes and nutrient requirements. Part 2. Comparison of proposals of SCF/EC with the recommendations of DGE). *Ernährungsumschau* **42**, 4–10.

Goode HF, Kelleher J & Walker BE (1989) Zinc concentrations in pure populations of peripheral blood neutrophils, lymphocytes and monocytes. *Annals of Clinical Biochemistry* **26**, 89–95.

Greskas D, Alivanis P, Kotzadamis N, Kiriazopoulos M & Tourkantonis A (1992) Influenza vaccination in chronic hemodialysis patients. The effect of zinc supplementation. *Renal Failure* **14**, 575–578.

Groman N & Judge K (1979) Effect of metal ions on diphtheria toxin production. *Infection and Immunity* **26**, 1065–1070.

Hadden JW (1995) The treatment of zinc is an immunotherapy. *International Journal of Immunopharmacology* **17**, 697–701.

Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. *Cell* **80**, 213–223.

Heng MK, Song MK & Heng MCY (1993) Reciprocity between tissue calmodulin and cAMP levels: modulation by excess zinc. *British Journal of Dermatology* **129**, 280–285.

Hogstrand C, Verbost PM, Bonga SE & Wood CM (1996) Mechanisms of zinc uptake in gills of freshwater rainbow trout: interplay with calcium transport. *American Journal of Physiology* **270**, R1141–R1147.

Humeny A, Bokenkamp D & Thole HH (1999) The HDQVH-motif in domain E of the estradiol receptor alpha is responsible for zinc-binding and zinc-induced hormone release. *Molecular and Cellular Endocrinology* **153**, 71–78.

Hynes M, Stone DM, Dowd M, Pitts-Meek S, Goddard A, Gurney A & Rosenthal A (1997) Control of cell pattern in the neural tube by the zinc finger transcription factor and oncogene Gli-1. *Neuron* **19**, 15–26.

Ishido M, Suzuki T, Adachi T & Kunimoto M (1999) Zinc stimulates DNA synthesis during its antiapoptotic action independently with increments of an antiapoptotic protein, Bcl-2, in porcine kidney LLC-PK cells. *Journal of Pharmacology and Experimental Therapeutics* **290**, 923–928.

James K (1990) Interaction between cytokines and α_2-macro-globulin. *Immunology Today* **11**, 163–166.

Jameson S (1993) Zinc status in pregnancy: the effect of zinc therapy on perinatal mortality, prematurity, and placental ablation. *Annals of the New York Academy of Sciences* **678**, 178–192.

Jiang S, Chow SC, McCabe MJ Jr & Orrenius S (1995) Lack of Ca2+ involvement in thymocyte apoptosis induced by chelation of intracellular Zn2+. *Laboratory Investigation* **73**, 111–117.

Kawahara M, Arispe N, Kuroda Y, Rojas E (1997) Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. *Biophysical Journal* **73**, 67–75.

Keen CL & Gershwin ME (1990) Zinc deficiency and immune function. *Annual Review of Nutrition* **10**, 415–431.

Kim J, Urban RG, Strominger JL & Wiley DC (1994) Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. *Science* **266**, 1870–1878.

Kirchner H & Rühl H (1970) Stimulation of human peripheral lymphocytes by Zn2+ in vitro. *Experimental Cell Research* **61**, 229–230.

Klaiman AP, Victery W, Kluger MJ & Vander AJ (1981) Urinary excretion of zinc and iron following acute injection of dead bacteria in dog. *Proceedings of the Society for Experimental Biology and Medicine* **167**, 165–171.

Klosterhalfen B, Töns C, Hauptmann S, Tietze L, Offner FA, Küpper W & Kirkpatrick CJ (1996) Influence of heat shock protein 70 and metallothionein induction by zinc-bis-(DL-hydrogenasaspartate) on the release of inflammatory mediators in a porcine model of recurrent endotoxemia. *Biochemical Pharmacology* **52**, 1201–1210.

Krasovec M & Frenk E (1996) Acrodermatitis enteropathica secondary to Crohn's disease. *Dermatology* **193**, 361–363.

Kreft B, Fischer A, Krüger S, Sack K, Kirchner H & Rink L (2000) The impaired immune response to diphtheria vaccination in elderly chronic hemodialysis patients is related to zinc deficiency. *Biogerontology* **1**, 61–66.

Kruse-Jarres JD (1989) The significance of zinc for humoral and cellular immunity. *Journal of Trace Elements and Electrolytes in Health and Diseases* **3**, 1–8.

Lighart GJ, Coberand JX, Fournier C, Galanaud P, Hijmans W, Kennes B, Müller-Hermelink HK & Steinmann GG (1984) Admission criteria for immunogerontological studies in man: The Senieur Protocol. *Mechanisms of Ageing and Development* **28**, 47–55.

Lin H, Zhu YJ & Lal R (1999) Amyloid beta protein (1–40) forms calcium permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. *Biochemistry* **38**, 11189–11196.

Maret W (1998) The glutathione redox state and zinc mobilization from metallothionein and other proteins with zinc-sulfur coordination sites. In *Glutathione in the Nervous System*, pp. 257–273 [CA Shaw, editor]. Philadelphia, PA: Taylor & Francis.

Maret W, Jacob C, Vallee BL & Fischer EH (1999) Inhibitory sites in enzymes: Zinc removal and reactivation by thionein. *Proceedings of the National Academy of Sciences USA* **96**, 1936–1940.

Mills CF (1989) *Zinc in Human Biology. Human Nutrition Reviews*. London: Springer Verlag.

Mocchegiani E, Santarelli L, Muzzioli M & Fabris N (1995*a*) Reversibility of the thymic involution and of age-related peripheral immune dysfunction by zinc supplementation in old mice. *International Journal of Immunopharmacology* **17**, 703–718.

Mocchegiani E, Veccia S, Ancarani F, Scalise G & Fabris N (1995*b*) Benefit of oral zinc supplementation as an adjunct to zidovudine (AZT) therapy against opportunistic infections in AIDS. *International Journal of Immunopharmacology* **17**, 719–727.

Mossad SB, Macknin ML, Medendorp SV & Mason P (1996) Zinc gluconate lozenges for treating the common cold. *Annals of Internal Medicine* **125**, 81–88.

Muraosa Y, Takahashi K, Yoshizawa M & Shibahara S (1996) cDNA cloning of a novel protein containing two zinc-finger domains that may function as a transcription factor for the human heme-oxygenase-1 gene. *European Journal of Biochemistry* **23**, 471–479.

Murthy ARK, Lehrer RI, Harwig SSL & Miyasaki KT (1993) In vitro candidastatic properties of the human neutrophil calpro-tectin complex. *Journal of Immunology* **151**, 6291–6301.

Myung SJ, Yang SK, Jung HY, Jung SA, Kang GH, Ha HK, Hong WS & Min Y (1998) Zinc deficiency manifested by dermatitis and visual dysfunction in a patient with Crohn's disease. *Journal of Gastroenterology* **33**, 876–879.

Najim RA, Sharquie KE & Farjou IB (1998) Zinc sulphate in the treatment of cutaneous leishmaniasis: an in vitro and animal study. *Memorias do Instituto Oswaldo Cruz* **93**, 831–837.

Nakayama H, Scott IC & Cross JC (1998) The transition to endoreduplication in trophoblast giant cells is regulated by the mSNA zinc finger transcription factor. *Developmental Biology* **199**, 150–163.

Neldner KH & Hambidge KM (1975) Zinc therapy in acro-dermatitis enteropathica. *New England Journal of Medicine* **292**, 879–882.

Neves I Jr, Bertho AL, Veloso VG, Nascimento DV, Campos-Mello DL & Morgado MG (1998) Improvement of the lympho-proliferative immune response and apoptosis inhibition upon in vitro treatment with zinc of peripheral blood mononuclear cells (PBMC) from HIV+ individuals. *Clinical and Experimental Immunology* **111**, 264–268.

Nowak G (1998) Alterations in zinc homeostasis in depression and antidepressant therapy. *Polish Journal of Pharmacology* **50**, 1–4.

Nowak G & Schlegel-Zawadzka M (1999) Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc. *Biological Trace Element Research* **67**, 85–92.

O'Halloran TV (1993) Transition metals in control of gene expression. *Science* **261**, 715–725.

Osati-Ashtiani F, King LE & Fraker PJ (1998) Variance in the resistance of murine early bone marrow B cells to a deficiency in zinc. *Immunology* **94**, 94–100.

Palmiter RD & Findley SD (1995) Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. *EMBO Journal* **14**, 639–649.

Palmiter RD, Cole TB & Findley SD (1996*a*) ZnT-2, a mammalian protein that confers resistance to zinc by facilitating vesicular sequestration. *EMBO Journal* **15**, 1784–1791.

Palmiter RD, Cole TB, Quaife CJ & Findley SD (1996*b*) ZnT-3, a putative transporter of zinc into synaptic vesicles. *Proceedings of the National Academy of Sciences USA* **93**, 14934–14939.

Patterson WP, Winkelmann M & Perry MC (1985) Zinc-induced copper deficiency: megamineral sideroblastic anemia. *Annals of Internal Medicine* **103**, 385–386.

Pavletich NP & Pabo CO (1993) Crystal structure of a five-finger GLI-DNA complex: new perspectives on zinc fingers. *Science* **261**, 1701–1707.

Philipsen S & Suske G (1999) A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. *Nucleic Acids Research* **27**, 2991–3000.

Phillips JL & Azari P (1974) Zinc transferrin: Enhancement of nucleic acid synthesis in phytohemagglutinin-stimulated human lymphocytes. *Cellular Immunology* **10**, 31–37.

Pohl E, Qui X, Must LM, Holmes RK & Hol WG (1997) Comparison of high-resolution structures of the diphteria toxin repressor in complex with cobalt and zinc at the cation-anion binding site. *Protein Science* **6**, 1114–1118.

Porter KG, McMaster D, Elmes ME & Love AH (1977) Anaemia and low serum-copper during zinc therapy. *Lancet* **ii**, 774.

Prasad AS (1995) Zinc: an overview. *Nutrition* **11**, 93–99.

Prasad AS (1996) Zinc deficiency in women, infants and children. *Journal of the American College of Nutrition* **15**, 113–120.

Prasad AS, Beck FW, Kaplan J, Chandrasekar PH, Ortega J, Fitzgerald JT & Swerdlow P (1999) Effect of zinc supplementation on incidence of infections and hospital admission in sickle cell disease (SCD). *American Journal of Hematology* **61**, 194–202.

Prasad AS, Miaie A Jr, Farid Z, Schulert A & Sandstead HH (1963) Zinc metabolism in patients with the syndrome of iron deficiency, hypogonadism and dwarfism. *Journal of Laboratory and Clinical Medicine* **83**, 537–549.

Provinciali M, Montenovo A, Di-Stefano G, Colombo M, Daghetta L, Cairati M, Veroni C, Cassino R, Della-Torre F & Fabris N (1998) Effect of zinc or zinc plus arginine supplementation on antibody titre and lymphocyte subsets after influenza vaccination in elderly subjects: a randomized controlled trial. *Age and Ageing* **27**, 715–722.

Rajagopalan S, Winter CC, Wagtmann N & Long EO (1995) The Ig-related killer cell inhibitory receptor binds zinc and requires zinc for recognition of HLA-C on target cells. *Journal of Immunology* **155**, 4143–4146.

Raulin J (1869) Etudes chimique sur la vegetation (Chemical studies on plants). *Annales des Sciences Naturelles Botanique et Biologie Vegetale* **11**, 293–299.

Rawer P, Willems WR, Breidenbach T, Guttmann W, Pabst W & Schutterle G (1987) Seroconversion rate hepatitis B vaccination, hemodialysis, and zinc supplementation. *Kidney International* **22S**, 149–152.

Reinhold D, Ansorge S & Grüngreiff K (1999) Immunobiology of zinc and zinc therapy. *Immunology Today* **20**, 102.

Rink L & Kirchner H (1999) Reply to Reinhold *et al*. *Immunology Today* **20**, 102–103.

Rühl H & Kirchner H (1978) Monocyte-dependent stimulation of human T cells by zinc. *Clinical and Experimental Immunology* **32**, 484–488.

Rühl H, Kirchner H & Borchert G (1971) Kinetics of the Zn^{2+}-stimulation of human peripheral lymphocytes in vitro. *Proceedings of the Society for Experimental Biology and Medicine* **137**, 1089–1092.

Safie-Garabedian B, Ahmed K, Khamashta MA, Taub NA & Hughes GRV (1993) Thymulin modulates cytokine release by peripheral blood mononuclear cells: a comparison between healthy volunteers and patients with systemic lupus erythematodes. *International Archives of Allergy and Immunology* **101**, 126–131.

Saha AR, Hadden EM & Hadden JW (1995) Zinc induces thymulin secretion from human thymic epithelial cells in vitro and augments splenocyte and thymocyte responses in vivo. *International Journal of Immunopharmacology* **17**, 729–733.

Sakai Y, Nakagawa R, Sato R & Maeda M (1998) Selection of DNA binding sites for human transcriptional regulator GATA-6. *Biochemical and Biophysical Research Communications* **250**, 682–688.

Salas M & Kirchner H (1987) Induction of interferon-γ in human leukocyte cultures stimulated by Zn^{2+}. *Clinical Immunology and Immunopathology* **45**, 139–142.

Sampson B, Kovar IZ, Rauscher A, Fairweather-Tait S, Beattie J, McArdle HJ, Ahmed R & Green C (1997) A case of hyperzincemia with functional zinc depletion: a new disorder? *Pediatric Research* **42**, 219–225.

Sandstead HH, Henriksen LK, Greger JL, Prasad AS & Good RA (1982) Zinc nutriture in the elderly in relation to taste acuity, immune response, and wound healing. *American Journal of Clinical Nutrition* **36**, 1046–1059.

Schoenmakers E, Alen P, Verrijdt G, Peeters B, Verhoeven G, Rombauts W & Claessens F (1999) Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains. *Biochemical Journal* **341**, 515–521.

Scholl TO, Hediger ML, Schall JI, Fischer RL & Khoo CS (1993) Low zinc intake during pregnancy: its association with preterm and very preterm delivery. *American Journal of Epidemiology* **137**, 1115–1124.

Scott BJ & Bradwell AR (1983) Identification of the serum binding proteins for iron, zinc, cadmium, nickel and calcium. *Clinical Chemistry* **29**, 629–633.

Scuderi P (1990) Differential effects of copper and zinc on human peripheral blood monocyte cytokine secretion. *Cellular Immunology* **126**, 391–405.

Shimizu N, Yamauchi Y & Aoki T (1999) Treatment and management of Wilson's disease. *Pediatrics International* **41**, 419–422.

Simkin PA (1976) Oral zinc sulphate in rheumatoid arthritis. *Lancet* **ii**, 539–542.

Skamoto A, Omirulleh S, Nakayama T & Iwabuchi M (1996) A zinc-finger-type transcription factor WZF-1 that binds to a novel *cis*-acting element of histone gene promoters represses its own promoter. *Plant and Cellular Physiology* **37**, 557–562.

Sohnle PG, Collins-Lech C & Wiessner JH (1991) The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. *Journal of Infectious Diseases* **164**, 137–142.

Song A, Chen YF, Thamatrakoln K, Storm TA & Krensky AM (1999) RFLAT-1: a new zinc finger transcription factor that activates RANTES gene expression in T lymphocytes. *Immunity* **10**, 93–103.

Sood SM, Wu MX, Hill KA & Slattery CW (1999) Characterization of zinc-depleted alanyl-tRNA synthetase from *Escherichia coli*: role of zinc. *Archives of Biochemistry and Biophysics* **368**, 380–384.

Sturniolo GC, Mestriner C, Irato P, Albergoni V, Longo G & D'Inca R (1999) Zinc therapy increases duodenal concentrations

of metallothionein and iron in Wilson's disease patients. *American Journal of Gastroenterology* **94**, 334–338.

Sundström M, Abrahamsen L, Antonsson P, Mehindate K, Mourad W & Dohlsten M (1996) The crystal structure of staphylococcal enterotoxin type D reveals Zn^{2+} mediated homodimerization. *EMBO Journal* **15**, 6832–6840.

Tanaka Y, Shiozawa S, Morimoto I & Fujita T (1989) Zinc inhibits pokeweed mitogen-induced development of immunoglobulin-secreting cells through augmentation of both CD4 and CD8 cells. *International Journal of Immunopharmacology* **11**, 673–679.

Taylor GA & Blackshear PJ (1995) Zinc inhibits turnover of labile mRNAs in intact cells. *Journal of Cellular Physiology* **162**, 378–387.

The Finnish-German APECED Consortium (1997) An auto-immune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. *Nature Genetics* **17**, 399–403.

Tierno PM Jr & Hanna BA (1985) In vitro amplification of toxic shock syndrome toxin-1 by intravaginal devices. *Contraception* **31**, 185–194.

Todd WK, Elvelym A & Hart EB (1934) Zinc in the nutrition of the rat. *American Journal of Physiology* **107**, 146–156.

Trubiani O, Antonucci A, Palka G & Di-Primio R (1996) Programmed cell death of peripheral myeloid precursor cells in Down patients: effect of zinc therapy. *Ultrastructural Pathology* **20**, 457–462.

Tsuda M, Imaizumi K, Katayama T, Kitagawa K, Wanaka A, Tohyama M & Takagi T (1997) Expression of zinc transporter gene, ZnT-1, is induced after transient forebrain ischemia in the gerbil. *Journal of Neuroscience* **17**, 6678–6684.

Turk S, Bozfakioglu S, Ecder ST, Kahraman T, Gurel N, Erkoc, Aysuna N, Turkmen A, Bekiroglu N & Ark E (1998) Effects of zinc supplementation on the immune system and on antibody response to multivalent influenza vaccine in hemodialysis patients. *International Journal of Artificial Organs* **21**, 274–278.

Turner J & Crossley M (1998) Cloning and characterization of mCtBP2, a co-repressor that associates with basic Kruppel-like factor and other mammalian transcriptional regulators. *EMBO Journal* **17**, 5129–5140.

Umezawa K, Nakazawa K, Uchihata Y & Otsuka M (1999) Screening for inducers of apoptosis in apoptosis-resistant human carcinoma cells. *Advances in Enzyme Regulation* **39**, 145–156.

Valberg LS, Flanagan PR & Chamberlain MJ (1984) Effect of iron, tin and copper on zinc absorption in humans. *American Journal of Clinical Nutrition* **40**, 536–541.

Vallee BL & Falchuk KH (1993) The biochemical basis of zinc physiology. *Physiological Reviews* **73**, 79–118.

Varadinova TL, Bontchev PR, Nachev CK, Shishkov SA, Strachilov D, Paskalev Z, Toutekova A & Panteva M (1993) Mode of action of Zn-complexes on herpes simplex virus type 1 infection in vitro. *Journal of Chemotherapy* **5**, 3–9.

Villiers MB, Gabert FM, Jacquier MR & Colomb MG (1993) Involvement of the Zn-binding region of the tetanus toxin in B and T recognition. Influence of Zn fixation. *Molecular Immunology* **30**, 129–136.

Warner GL & Lawrence DA (1986) Stimulation of murine lymphocyte response by cations. *Cellular Immunology* **101**, 425–439.

Weiss G, Wachter H & Fuchs D (1995) Linkage of cell-mediated immunity to iron metabolism. *Immunology Today* **16**, 495–500.

Weiss G, Widner B, Zoller H & Fuchs D (1998) The immunobiology of zinc and the kidney. *Immunology Today* **19**, 193.

Wellinghausen N, Driessen C & Rink L (1996*a*) Stimulation of human peripheral blood mononuclear cells by zinc and related cations. *Cytokine* **18**, 767–771.

Wellinghausen N, Fischer A, Kirchner H & Rink L (1996*b*) Interaction of zinc ions with human peripheral blood mononuclear cells. *Cellular Immunology* **171**, 255–261.

Wellinghausen N, Kern WV, Jöchle W & Kern P (2000) Zinc serum level in human deficiency virus infected patients in relation to immunological status. *Biological Trace Element Research* **73**, 79–89.

Wellinghausen N, Kirchner H & Rink L (1997*a*) The immunobiology of zinc. *Immunology Today* **18**, 519–521

Wellinghausen N, Martin M & Rink L (1997*b*) Zinc inhibits IL-1 dependent T cell stimulation. *European Journal of Immunology* **27**, 2529–2535.

Wellinghausen N, Schromm AB, Seydel U, Brandenburg K, Luhm J, Kirchner H & Rink L (1996*c*) Zinc enhances lipo-polysaccharide-induced monokine secretion by a fluidity change of lipopolysaccharide. *Journal of Immunology* **157**, 3139–3145.

Williams AJ, Khachigian LM, Shows T & Collins T (1995) Isolation and characterization of a novel zinc-finger protein with transcription repressor activity. *Journal of Biological Chemistry* **270**, 22143–22152.

Worwag M, Classen HG & Schumacher E (1999) Prevalence of magnesium and zinc in nursing home residents in Germany. *Magnesium Research* **12**, 181–189.

Wright SD & Kolesnick RN (1995) Does endotoxin stimulate cells by mimicking ceramide? *Immunology Today* **16**, 297–302.

Yamagata K, Kaufmann WE, Lanahan A, Papapavlou M, Barnes CA, Andreasson KI & Worley PF (1994) Egr3/Pilot, a zinc finger transcription factor, is rapidly regulated by activity in brain neurons and colocalizes with Egr1/zif268. *Learning and Memory* **1**, 140–152.

Yang XW, Zhong R & Heintz N (1996) Granule cell specification in the developing mouse brain as defined by expression of the zinc finger transcription factor RU49. *Development* **122**, 555–566.

Yuzbasiyan-Gurkan VA, Brewer GJ, Vander AJ, Guenter MJ & Prasad AS (1989) Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia. *American Journal of Hematology* **31**, 87–90.

Zalewski PD & Forbes IJ (1993) Intracellular zinc and the regulation of apoptosis. In *Programmed Cell Death: The Cellular and Molecular Biology of Apoptosis*, pp. 73–85 [M Laviri and D Watters, editors]. Melbourne: Harword Academic Press.

Ziegler EE, Serfass RE, Nelson SE, Figueroa-Colon R, Edwards BB, Houk RS & Thompson JJ (1989) Effect of low zinc intake on absorption and excretion of zinc by infants studied with ^{70}Zn as extrinsic tag. *Journal of Nutrition* **119**, 1647–1653.

Zoli A, Altomonte L, Caricchio R, Gaossi A, Mirone L, Ruffini MP & Magaro M (1998) Serum zinc and copper in active rheumatoid arthritis: correlation with interleukin 1 beta and tumour necrosis factor alpha. *Clinical Rheumatology* **17**, 378–382.